C26 ASTHMA IN INFANTS AND CHILDREN: Tiotropium Respimat® Add-On Therapy Is Effective In Children And Adolescents With Severe Symptomatic Asthma, Irrespective Of Immunoglobulin E Levels And Eosinophil Count

In these patients, tiotropium Respimat® add-on therapy has demonstrated efficacy and safety. Since allergic asthma is the most common phenotype (Schatz & Rosenwasser, 2014), we assessed whether tiotropium Respimat® add-on to ICS + other controllers is effective in patients aged 6-17 years with s...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Main Authors: Goldstein, S, Vogelberg, C, Hamelmann, E, Szefler, S J, Mansfield, L, Voelker, B, El Azzi, G, Sigmund, R, Engel, M, Vandewalker, M
Format: Article
Language:English
Subjects:
Asthma
Immunoglobulins
Respiratory therapy
Teenagers
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In these patients, tiotropium Respimat® add-on therapy has demonstrated efficacy and safety. Since allergic asthma is the most common phenotype (Schatz & Rosenwasser, 2014), we assessed whether tiotropium Respimat® add-on to ICS + other controllers is effective in patients aged 6-17 years with severe symptomatic asthma, irrespective of potential allergic asthma status, assessed via baseline immunoglobulin E (IgE) levels and blood eosinophil counts. Post hoc analyses of the pooled trials were performed to predict differences in lung function responses and time to first exacerbation for tiotropium versus placebo across the full range of baseline total serum IgE levels (0-2000 µg/L) and blood eosinophil counts (0-2000 cells/µL) in the trial population.
ISSN:1073-449X
1535-4970